Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Bortezomib + Ascorbic Acid + Melphalan (BAM) Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma

NCT00317811 is registered in ClinicalTrials.gov with Oncotherapeutics as lead sponsor.

NCT NCT00317811
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00317811 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Bortezomib + Ascorbic Acid + Melphalan (BAM) Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma
Lead sponsor
Oncotherapeutics
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2005
Completion date
Not reported
Enrollment
35 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma and plasma cell neoplasm